TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00813943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
Study: NCT01209104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: 100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: 100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
Study: NCT01008241

Intervention type: BEHAVIORAL
Intervention: Paper questionnaire
Description: Participants will complete a paper and pencil questionnaire that measures 4 domains of interest (advanced care planning; end of life care; hospice care and death and dying) as well as demographic factors (age, marital status, education etc.)
Study: NCT01410357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Training in Illness Management (TTIM)
Description: This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
Study: NCT02845219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once daily alone or together with oral contraceptive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNAC
Description: Oral administration once daily together with oral contraceptive.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: Oral administration once daily alone or together with oral semaglutide or SNAC.
Study: NCT03560700

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactobacillus probiotic strain
Description: Approved Dietary supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study: NCT01505894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study: NCT02775019

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: 2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
Study: NCT01505894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study: NCT03480802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study: NCT01703000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (NG PROMUS)
Description: Interventional coronary artery stenting with NG PROMUS study stent.
Study: NCT00289913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: VAQTA™
Description: VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: VAQTA™
Description: VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: VAQTA™
Description: VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: VAQTA™
Description: VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: VAQTA™
Description: VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Infanrix™
Description: Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis~Vaccine Adsorbed, GlaxoSmithKline).~One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit.
Study: NCT02775019

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
Study: NCT00288899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced surgical iMedConsent process (with repeat back)
Description: Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand.

Intervention type: OTHER
Group type: OTHER
Intervention: standard surgical iMedConsent process
Description: Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
Study: NCT01198522

Intervention type: DRUG
Group type: OTHER
Intervention: L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine
Description: Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29.
Study: NCT00205270

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season
Study: NCT01268280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg CK-2017357
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.
Study: NCT04844710

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: acupuncture and standard care
Description: manual acupuncture in acupoint LI4, LI11, ST36 every 2 days for 6 times standard care

Intervention type: DRUG
Group type: OTHER
Intervention: standard care
Description: standard care only
Study: NCT01199367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2450 in combination with lapatinib and letrozole
Description: Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
Study: NCT02396160

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Urox
Description: Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
Study: NCT02236182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide low dose
Study: NCT03717350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100ml of sodium chloride 0.9% within 15 minutes intravenously once
Study: NCT02236182

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide high dose
Study: NCT00234286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfort care education intervention
Description: Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
Study: NCT01650012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplerenone
Description: target 50 mg per day titrated down for hyperkalemia or hypotension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02085642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Single disposal needle to be used, 0.02 mm x 25 mm in length

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needle
Description: Retractable needle with no skin puncture
Study: NCT03005873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599 LD group
Description: Single dose via intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single dose via intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599 HD group
Description: Single dose via intra-articular injection
Study: NCT02489929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Study: NCT00859638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: group self-management classes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: group self-management classes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capacity Building
Description: workshops and case reviews with primary health care team members
Study: NCT01713933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System
Description: Focused ultrasound energy delivered below the surface of the skin.
Study: NCT01488123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized manualized Ayurvedic intervention
Description: The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
Study: NCT00146159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: dosage
Study: NCT00791973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate
Description: 2 puffs in each nostril once daily for 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate
Description: 2 puffs in each nostril once daily for 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 puffs in each nostril once daily for 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 puffs in each nostril once daily for 1 week
Study: NCT00977301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosamprenavir/ritonavir
Description: 16 days 700mg/100mg RTV BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 15 mg olanzapine single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 10 mg olanzapine single dose
Study: NCT04371874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin
Description: The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
Study: NCT01104376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily.
Study: NCT00797966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Tablets, 10 - 225 mgs, dose once daily, 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADT
Description: Tablets, 10 - 225 mgs, dose once daily, 14 weeks
Study: NCT00732901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily days 1-28
Study: NCT00732043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate extract
Description: 8 oz per day, 48 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate juice
Description: 8 oz per day, 48 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 8 oz per day, 48 months
Study: NCT04280809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Description: GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2. Each patient was irradiated 3 times consecutively right after surgery, day 1 and day 2 after surgery
Study: NCT04374227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Body regions that were treated included head, cervical, thoracic, ribs, lumbar, pelvis, sacrum, lower extremity, and upper extremity.
Study: NCT01031420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single arm dose dense MVAC
Description: standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.